Literature DB >> 17714757

Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Samer Z Al-Quran1, Lijun Yang, James M Magill, Raul C Braylan, Vonda K Douglas-Nikitin.   

Abstract

Assessment of bone marrow involvement by malignant plasma cells is an important element in the diagnosis and follow-up of patients with multiple myeloma and other plasma cell dyscrasias. Microscope-based differential counts of bone marrow aspirates are used as the primary method to evaluate bone marrow plasma cell percentages. However, multiple myeloma is often a focal process, a fact that impacts the accuracy and reliability of the results of bone marrow plasma cell percentages obtained by differential counts of bone marrow aspirate smears. Moreover, the interobserver and intraobserver reproducibility of counting bone marrow plasma cells microscopically has not been adequately tested. CD138 allows excellent assessment of plasma cell numbers and distribution in bone marrow biopsies. We compared estimates of plasma cell percentages in bone marrow aspirates and in hematoxylin-eosin- and CD138-stained bone marrow biopsy sections (CD138 sections) in 79 bone marrows from patients with multiple myeloma. There was a notable discrepancy in bone marrow plasma cell percentages using the different methods of observation. In particular, there was a relatively poor concordance of plasma cell percentage estimation between aspirate smears and CD138 sections. Estimates of plasma cell percentage using CD138 sections demonstrated the highest interobserver concordance. This observation was supported by computer-assisted image analysis. In addition, CD138 expression highlighted patterns of plasma cell infiltration indicative of neoplasia even in the absence of plasmacytosis. We conclude that examination of CD138 sections should be considered for routine use in the estimation of plasma cell load in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714757      PMCID: PMC3419754          DOI: 10.1016/j.humpath.2007.04.010

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  35 in total

1.  Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.

Authors:  Andrew Wei; David Westerman; Frank Feleppa; Melanie Trivett; Surender Juneja
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

2.  Guidelines on the diagnosis and management of multiple myeloma 2005.

Authors:  Alastair Smith; Finn Wisloff; Diana Samson
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

3.  Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment.

Authors:  Kristi J Smock; Sherrie L Perkins; David W Bahler
Journal:  Arch Pathol Lab Med       Date:  2007-06       Impact factor: 5.534

Review 4.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

5.  The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells.

Authors:  Ashley P Ng; Andrew Wei; Dinesh Bhurani; Peter Chapple; Frank Feleppa; Surender Juneja
Journal:  Haematologica       Date:  2006-07       Impact factor: 9.941

6.  Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.

Authors:  G Jego; N Robillard; D Puthier; M Amiot; F Accard; D Pineau; J L Harousseau; R Bataille; C Pellat-Deceunynck
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

Review 7.  Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.

Authors:  M V Dhodapkar; R D Sanderson
Journal:  Leuk Lymphoma       Date:  1999-06

8.  Usefulness and reproducibility of cytomorphologic evaluations to differentiate myeloma from monoclonal gammopathies of unknown significance.

Authors:  F Millá; A Oriol; J Aguilar; A Aventín; R Ayats; E Alonso; A Domingo; E Feliu; L Florensa; A López; E Pérez-Vila; M Rozman; C Sánchez; T Vallespí; S Woessner
Journal:  Am J Clin Pathol       Date:  2001-01       Impact factor: 2.493

9.  Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Authors:  S Rajkumar; R Fonseca; M Lacy; T Witzig; J Lust; P Greipp; T Therneau; R Kyle; M Litzow; M Gertz
Journal:  Bone Marrow Transplant       Date:  1999-09       Impact factor: 5.483

10.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Authors:  M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

View more
  11 in total

1.  An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.

Authors:  Ariosto Silva; Timothy Jacobson; Mark Meads; Allison Distler; Kenneth Shain
Journal:  J Vis Exp       Date:  2015-07-15       Impact factor: 1.355

Review 2.  Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.

Authors:  Uday Yanamandra; Navin Khattry; Shaji Kumar; Noopur Raje; Arihant Jain; Sundar Jagannath; Hari Menon; Lalit Kumar; Neelam Varma; Subhash Varma; Tapan Saikia; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-02       Impact factor: 0.900

3.  Plasmablastic Lymphoma of Small Intestine: A Rare Case Report with Review of Literature.

Authors:  Rachna Khera; Faiq Ahmed; Sudha S Murthy; Krishna Mohan Mallavarapu
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-17       Impact factor: 0.900

4.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

5.  Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories.

Authors:  Shashirekha Shetty; Marion Siady; Kalyan C Mallempati; Andrew Wilson; Jeff Poarch; Brandon Chandler; Judy Gray; Mohamed E Salama
Journal:  Int J Hematol       Date:  2012-02-11       Impact factor: 2.490

6.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

7.  Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma.

Authors:  N Lee; S Y Moon; J-H Lee; H-K Park; S-Y Kong; S-M Bang; J H Lee; S-S Yoon; D S Lee
Journal:  Blood Cancer J       Date:  2017-02-17       Impact factor: 11.037

8.  Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study.

Authors:  Jasmita Dass; Sudheer Arava; Pravas Chandra Mishra; Amit Kumar Dinda; Hara Prasad Pati
Journal:  South Asian J Cancer       Date:  2019 Jan-Mar

9.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

10.  Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Authors:  A Visram; C Soof; S V Rajkumar; S K Kumar; S Bujarski; T M Spektor; R A Kyle; J R Berenson; A Dispenzieri
Journal:  Blood Cancer J       Date:  2021-06-24       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.